Body Composition and Markers of Cardiometabolic Health in Transgender Youth Compared With Cisgender Youth.
Adipose Tissue
Adolescent
Adult
Biomarkers
/ analysis
Body Composition
Body Mass Index
Cardiovascular Diseases
/ diagnosis
Case-Control Studies
Child
Child, Preschool
Cross-Sectional Studies
Female
Follow-Up Studies
Humans
Infant
Infant, Newborn
Insulin Resistance
Male
Pilot Projects
Prognosis
Transgender Persons
/ statistics & numerical data
Young Adult
body composition
estradiol
insulin resistance
testosterone
transgender
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
01 03 2020
01 03 2020
Historique:
received:
11
04
2019
accepted:
20
09
2019
pubmed:
24
9
2019
medline:
11
11
2020
entrez:
24
9
2019
Statut:
ppublish
Résumé
As many as 1.8% of adolescents identify as transgender and many more seek care, yet the impact of gender-affirming hormone therapy (GAHT) on cardiometabolic health is unknown. To determine insulin sensitivity and body composition among transgender females (TF) and males (TM) on estradiol or testosterone, compared with cisgender females (CF) and males (CM). Pilot, cross-sectional study conducted from 2016-2018. Academic regional transgender referral center. Transgender adolescents on either testosterone or estradiol for at least 3 months were recruited. Nineteen TM were matched to 19 CM and 42 CF on pubertal stage and body mass index (BMI). Eleven TF were matched to 23 CF and 13 TF to 24 CM on age and BMI. 1/[fasting insulin] and body composition (dual-energy x-ray absorptiometry). Total body fat was lower in TM than CF mean ± SD: (29% ± 7% vs 33% ± 7%; P = 0.002) and higher than in CM (28% ± 7% vs 24% ± 9%; P = 0.047). TM had higher lean mass than CF (68% ± 7% vs 64% ± 7%, P = 0.002) and lower than CM (69% ± 7% vs 73% ± 8%; P = 0.029). Insulin sensitivity was not different between the groups.TF had lower body fat than CF (31% ± 7% vs 35% ± 8%; P = 0.033) and higher than CM (28% ± 6% vs 20% ± 10%; P = 0.001). TF had higher lean mass than CF (66% ± 6% vs 62% ± 7%; P = 0.032) and lower than CM (69% ± 5% vs 77% ± 9%; P = 0.001). TF were more insulin resistant than CM (0.078 ± 0.025 vs 0.142 ± 0.064 mL/μU; P = 0.011). Transgender adolescents on GAHT have significant differences in body composition compared with cisgender controls, with a body composition intermediate between BMI-matched CMs and CFs. These changes in body composition may have consequences for the cardiometabolic health of transgender adolescents. NCT02550431.
Identifiants
pubmed: 31544944
pii: 5572616
doi: 10.1210/clinem/dgz029
pmc: PMC7112978
pii:
doi:
Substances chimiques
Biomarkers
0
Banques de données
ClinicalTrials.gov
['NCT02550431']
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NHLBI NIH HHS
ID : K24 HL145076
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK048520
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© Endocrine Society 2019.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Clin Endocrinol Metab. 2017 Nov 1;102(11):3869-3903
pubmed: 28945902
Arch Dis Child. 1969 Jun;44(235):291-303
pubmed: 5785179
MMWR Morb Mortal Wkly Rep. 2019 Jan 25;68(3):67-71
pubmed: 30677012
JAMA. 2014 May 7;311(17):1778-86
pubmed: 24794371
Int J Cardiol. 2014 Feb 15;171(3):398-403
pubmed: 24405838
Eur J Endocrinol. 2013 Sep 13;169(4):471-8
pubmed: 23904280
Diabetes. 1999 Oct;48(10):2039-44
pubmed: 10512371
Endocrinology. 2010 May;151(5):2040-9
pubmed: 20211973
Lipids. 1979 Jan;14(1):113-8
pubmed: 218068
J Clin Endocrinol Metab. 2008 Jan;93(1):19-25
pubmed: 17986639
J Endocr Soc. 2018 Mar 05;2(4):349-360
pubmed: 29577110
Curr Opin Endocrinol Diabetes Obes. 2009 Feb;16(1):10-5
pubmed: 19115520
J Appl Physiol (1985). 1989 Jan;66(1):498-503
pubmed: 2917954
J Adolesc Health. 2016 Mar;58(3):369-71
pubmed: 26903434
Vital Health Stat 11. 2002 May;(246):1-190
pubmed: 12043359
J Clin Endocrinol Metab. 2011 Jan;96(1):159-67
pubmed: 20962021
PLoS One. 2012;7(12):e52036
pubmed: 23300589
J Clin Endocrinol Metab. 2011 Jul;96(7):2136-45
pubmed: 21508130
Best Pract Res Clin Endocrinol Metab. 2013 Feb;27(1):13-24
pubmed: 23384742
Andrologia. 2017 Jun;49(5):
pubmed: 27572683
J Clin Endocrinol Metab. 1994 Jul;79(1):265-71
pubmed: 8027240
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
J Sex Med. 2018 Feb;15(2):251-260
pubmed: 29425666
J Diabetes Complications. 2016 Aug;30(6):1103-10
pubmed: 27133451
Hypertension. 2007 Apr;49(4):839-45
pubmed: 17309946
Arch Dis Child. 1970 Feb;45(239):13-23
pubmed: 5440182
Diabetes Obes Metab. 2017 Dec;19(12):1805-1809
pubmed: 28452101
J Clin Endocrinol Metab. 2019 Oct 1;104(10):4390-4397
pubmed: 30985874
J Clin Endocrinol Metab. 2017 Nov 1;102(11):3914-3923
pubmed: 28945852
Pediatrics. 2017 May;139(5):
pubmed: 28557738
Oman Med J. 2012 Nov;27(6):471-4
pubmed: 23226817
Circulation. 2019 Mar 12;139(11):1461-1462
pubmed: 30776252
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Int J Obes (Lond). 2006 Apr;30(4):598-602
pubmed: 16570089